NCT00439010View on ClinicalTrials.gov

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Alzheimers Disease
Interventions
DRUG

[123I] AV 39

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven

Sponsors
All Listed Sponsors
collaborator

Institute for Neurodegenerative Disorders

OTHER

lead

Molecular NeuroImaging

OTHER